dedifferentiated liposarcoma
Disease Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0080531
Name dedifferentiated liposarcoma
Definition A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma dedifferentiated liposarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01506596 Phase II Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed USA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Active, not recruiting USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS 2
NCT04028063 Phase II Botensilimab + Doxorubicin Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04438824 Phase II Palbociclib + Retifanlimab Palbociclib and INCMGA00012 in People With Advanced Liposarcoma Active, not recruiting USA 0
NCT04668300 Phase II Durvalumab + Oleclumab Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) Active, not recruiting USA 0
NCT04874311 Phase II Bintrafusp alfa + Doxorubicin Doxorubicin Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) Recruiting FRA 0
NCT04967521 Phase III Abemaciclib SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT04979442 Phase III Trabectedin Milademetan Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) (MANTRA) Terminated USA | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT 4
NCT04996004 Phase Ib/II Doxorubicin + TTI-621 A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma Terminated USA 0
NCT05043649 Phase I Camsirubicin + Pegfilgrastim Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Terminated USA 0
NCT05116683 Phase II ATX101 ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101) Terminated USA 0
NCT05218499 Phase II BI 907828 Doxorubicin Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Active, not recruiting USA | TUR | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS 5
NCT05580588 Phase II SPH4336 Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Terminated USA 0
NCT05597917 Phase III Trabectedin Trabectedin + tTF-NGR tTF-NGR Randomized Study - STS (TRABTRAP) Recruiting DEU 0
NCT05694871 Phase II Cemiplimab + Palbociclib Palbociclib Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT05711615 Phase I Pegylated liposomal doxorubicin + Peposertib Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Recruiting USA 0
NCT05879185 Phase II Izuralimab A Study of XmAb23104 in People With Sarcoma Terminated USA 0
NCT05886634 Phase II Etrumadenant + Zimberelimab A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT06058793 Phase III BI 907828 Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Active, not recruiting USA | GBR | CAN | BRA | AUS | ARG 1
NCT06116578 Phase II Pembrolizumab Olaparib + Pembrolizumab Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc) Withdrawn FRA 0
NCT06263231 Phase III Eribulin Trabectedin Pazopanib INT230-6 A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) Active, not recruiting USA | FRA | ESP | DEU | CAN 0
NCT06389799 Phase II Pemigatinib + Retifanlimab A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI) Recruiting SWE | NOR 0
NCT06414434 Phase I BTX-A51 BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma Recruiting USA 0
NCT06422806 Phase III Doxorubicin Doxorubicin + Pembrolizumab Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Recruiting USA | CAN 1
NCT06498648 Phase Ib/II Abemaciclib + Gemcitabine Docetaxel + Gemcitabine Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Suspended USA 0
NCT06578624 Phase Ib/II SA53-OS Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06789172 Phase I OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395 A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE) Recruiting USA | GBR | AUS 0
NCT06843967 Phase I Mirdametinib + Palbociclib A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma Recruiting USA 0
NCT07027423 Phase I BOLD-100 + Doxorubicin BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas Not yet recruiting CAN 0
NCT07049848 Phase II Atezolizumab Atezolizumab + Doxorubicin SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma Recruiting USA 0